SynthesisActa diabetologica2023
Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: a systematic review and meta-analysis of clinical trials and observational studies.
Synthesis in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.Journal of endocrinological investigation · 2025Guideline
- Impact of herpes zoster and post-zoster SGLT2 inhibitors initiation on cardiorenal outcomes in type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Beyond the Virological Benefits of the Herpes Zoster Vaccine in the Context of Primary Care.Vaccines · 2026Article
- Outcomes of Single versus Repeated High-Voltage Pulsed Radiofrequency for Thoracic Herpes Zoster Neuralgia in Patients with Diabetes Mellitus: A Retrospective Study.Journal of pain research · 2026Article
- Herpes zoster hospitalization as a sentinel signal for undiagnosed dysglycemia: a call for routine glycemic screening in clinical practice.Frontiers in clinical diabetes and healthcare · 2026Article
- Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation.BMC medicine · 2025Article
- Comorbidities in hospitalized patients with herpes zoster: an Italian retrospective observational study in the years 2011-2023.BMC infectious diseases · 2025Observational
- Review
- Vaccinome Landscape in Nearly 620 000 Patients With Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
- Prophylactic vaccination strategies for adult patients with diabetes: a narrative review of safety profiles and clinical effectiveness.Clinical and experimental vaccine research · 2025Review
- Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy.Vaccines · 2025Review
- Comment on Limitations of "Assessing Herpes Zoster Vaccine Efficacy in Patients With Diabetes: A Community-Based Cohort Study".Journal of medical virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe risk for Herpes zoster (HZ) and its complications is higher in people with diabetes mellitus (DM). Our aim is to assess efficacy and effectiveness of the currently available live-attenuated zoster vaccine (LZV) and recombinant zoster vaccine (RZV) in adults with DM.
methodsA Systematic Review and Meta-analysis of clinical trials and observational studies comparing incidence of HZ and its complications in vaccinated and unvaccinated people with DM was performed, on PubMed, Cochrane, Clinical Trials.gov and Embase databases, up to January 15th, 2023. Risk of bias was assessed through the Cochrane Collaboration tool and the Newcastle-Ottawa Scale. The protocol was registered on the PROSPERO website (CRD42022370705).
resultsOnly three observational studies reported LZV efficacy and effectiveness in people with DM. A lower risk for HZ infection (MH-OH Ratio 95% CI = 0.52 [0.49, 0.56] was observed, for unadjusted analysis, and 0.51 [0.46, 0.56] for adjusted analysis, both with P < 0.00001 and no heterogeneity). No data on LZV safety were reported. A pooled analysis of two trials comparing RZV and placebo, showed a reduced risk for HZ incidence: (95% CI Odds Ratio: 0.09 [0.04-0.19]), with no difference in severe adverse events and mortality.
conclusionsIn our meta-analysis of three observational studies LZV showed a 48% effectiveness in reducing HZ incidence in adults with diabetes whereas in a pooled analysis of two RCTs, RZV showed a 91% efficacy. No data are available on the effects of vaccination on the incidence and severity of HZ-related complications among subjects with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.